CFO
TMO icon

Callan Family Office’s Thermo Fisher Scientific TMO Stock Holding History

Callan Family Office’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.09M Sell
18,496
-1,606
-8% -$872K 0.21% 91
2025
Q4 		$11.6M Buy
20,102
+3,757
+23% +$2.12M 0.25% 76
2025
Q3 		$7.93M Buy
16,345
+312
+2% +$145K 0.25% 83
2025
Q2 		$6.5M Buy
16,033
+4,146
+35% +$1.73M 0.21% 116
2025
Q1 		$5.91M Sell
11,887
-2,147
-15% -$1.16M 0.44% 50
2024
Q4 		$7.3M Buy
14,034
+9,012
+179% +$4.95M 0.46% 41
2024
Q3 		$3.11M Buy
5,022
+871
+21% +$516K 0.52% 37
2024
Q2 		$2.3M Buy
4,151
+2,864
+223% +$1.64M 0.44% 38
2024
Q1 		$748K Buy
1,287
+503
+64% +$282K 0.18% 50
2023
Q4 		$416K Buy
784
+97
+14% +$47K 0.1% 62
2023
Q3 		$348K Sell
687
-462
-40% -$246K 0.09% 65
2023
Q2 		$599K Sell
1,149
-1,138
-50% -$614K 0.16% 58
2023
Q1 		$1.32M Buy
2,287
+1,006
+79% +$567K 0.32% 47
2022
Q4 		$705K Buy
+1,281
New +$679K 0.23% 46

Other funds holding TMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Callan Family Office's TMO Position: Q1 2026 in Review

Callan Family Office reduced its Thermo Fisher Scientific (TMO) stake by 8% in Q1 2026, selling an estimated $872K and leaving 18,496 shares worth $9.09M. The position accounts for 0.21% of the portfolio, ranked #91.

Callan Family Office first reported a position in TMO in Q4 2022 and has held it in 14 quarters since. The position peaked at $11.6M in Q4 2025. 2,588 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

  • Callan Family Office held 18,496 shares of Thermo Fisher Scientific worth $9.09M as of Q1 2026.
  • Callan Family Office sold 1,606 Thermo Fisher Scientific shares in Q1 2026, an estimated $872K.
  • Thermo Fisher Scientific made up 0.21% of Callan Family Office's portfolio in Q1 2026, its #91 holding.
  • Callan Family Office first reported a position in Thermo Fisher Scientific in Q4 2022 and has held it in 14 quarters since.
  • Callan Family Office's Thermo Fisher Scientific position peaked at $11.6M in Q4 2025.
  • 2,588 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Callan Family Office's 13F filing for Q1 2026, filed 13 May 2026.